AdAlta uses its proprietary antibody libraries, derived from shark antibodies and human proteins with shark antibody properties (i-bodies), to develop new therapeutics targeting cancer. AdAlta’s next generation antibodies have a unique structure with the potential to bind new therapeutic targets that are difficult to address using traditional antibodies. They are also smaller than conventional antibodies making them easier and cheaper to manufacture. Visit www.adalta.com.au for more information.
Yuuwa is looking forward to supporting AdAlta in demonstrating the efficacy of its next generation antibody technology and the licensing of the libraries to pharmaceutical companies.
The Press Announcement is linked here: Yuuwa AdAlta Agreement Press Release